Hosted on MSN
Standard BioTools outlines $165M-$175M revenue target for FY2025 while driving proteomics partnerships
CEO Michael Egholm highlighted that Standard BioTools delivered Q1 2025 revenues of $40.8 million, aligned with their plan despite a challenging operating backdrop. He emphasized improvements in ...
Standard BioTools (LAB Quick Quote LAB - Free Report) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago ...
Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment ...
BOSTON, Mass. and WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools”) and Treeline Biosciences, Inc. ("Treeline”) today announced they have ...
Commenting on the ISS recommendation, SomaLogic issued the following statement: SomaLogic is pleased that ISS shares its belief that the merger with Standard BioTools is in the best interests of all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results